Lupus is a medical condition with an aura of mystery. Symptoms affect each patient differently and can mimic other disorders. There’s no single “lupus test” to pinpoint the disease.
Lupus is one of more than 100 known autoimmune disorders. With these conditions, a person’s immune system mistakes the body’s own healthy cells for outside invaders, creating auto-antibodies, proteins that target and attack these cells.
Skin rashes, patchy hair loss, fatigue, and joint pain and swelling can raise the suspicion of lupus, particularly in younger women, who are at highest risk. But because systemic lupus erythematosus, the most common form, can affect almost any part of the body, symptoms and complications could also include unexplained seizures, kidney disease or heart disease. Some may experience one set of signs and symptoms while others experience a completely different set.
Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.
